.Pharmacolibrary.Drugs.ATC.S.S01GA07

Information

Brimonidine is an alpha-2 adrenergic receptor agonist used primarily in ophthalmology to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is administered as an ophthalmic solution and is an approved and currently used drug.

Pharmacokinetics

Pharmacokinetic parameters in adults following topical ocular administration under steady-state conditions.

References

1. Ackerman, SL, et al., & Vittitow, JL (2019). Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Clinical & experimental optometry 102(2) 131–139. DOI:10.1111/cxo.12846 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30525235

2. Schnichels, S, et al., & Herrmann, A (2021). Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles. ACS applied materials & interfaces 13(8) 9445–9456. DOI:10.1021/acsami.0c18626 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33528240

3. Kim, CY, et al., & Seong, GJ (2007). Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 23(5) 481–486. DOI:10.1089/jop.2007.0042 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17900227

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)